International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Chemotherapy-treated Cancer Patients at Risk for Febrile Neutropenia and Treated Prophylactically With Filgrastim Biosimilar.

Trial Profile

International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Chemotherapy-treated Cancer Patients at Risk for Febrile Neutropenia and Treated Prophylactically With Filgrastim Biosimilar.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Febrile neutropenia
  • Focus Therapeutic Use
  • Acronyms Monitor-GCSF
  • Sponsors Sandoz
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top